268 related articles for article (PubMed ID: 28467522)
1. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.
Freites-Martinez A; Kwong BY; Rieger KE; Coit DG; Colevas AD; Lacouture ME
JAMA Dermatol; 2017 Jul; 153(7):694-697. PubMed ID: 28467522
[TBL] [Abstract][Full Text] [Related]
2. Multiple Keratoacanthoma-like Lesions in a Patient Treated with Pembrolizumab.
Fradet M; Sibaud V; Tournier E; Lamant L; Boulinguez S; Brun A; Pages C; Meyer N
Acta Derm Venereol; 2019 Dec; 99(13):1301-1302. PubMed ID: 31449315
[No Abstract] [Full Text] [Related]
3. [Keratoacanthomas on recent tattoos: Two cases].
Kluger N; Douvin D; Dupuis-Fourdan F; Doumecq-Lacoste JM; Descamps V
Ann Dermatol Venereol; 2017 Dec; 144(12):776-783. PubMed ID: 29126557
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Coscarart A; Martel J; Lee MP; Wang AR
J Cutan Pathol; 2020 Mar; 47(3):275-279. PubMed ID: 31589773
[TBL] [Abstract][Full Text] [Related]
5. Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy.
Sanders S; Busam KJ; Halpern AC; Nehal KS
Dermatol Surg; 2002 Oct; 28(10):954-8. PubMed ID: 12410683
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
Sanlorenzo M; Vujic I; Daud A; Algazi A; Gubens M; Luna SA; Lin K; Quaglino P; Rappersberger K; Ortiz-Urda S
JAMA Dermatol; 2015 Nov; 151(11):1206-1212. PubMed ID: 26222619
[TBL] [Abstract][Full Text] [Related]
7. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
8. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
9. Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab.
Chaudhari S; Leon A; Levin E; Neuhaus I; Liao W
J Drugs Dermatol; 2017 May; 16(5):513-515. PubMed ID: 28628690
[TBL] [Abstract][Full Text] [Related]
10. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
Kao JC; Liao B; Markovic SN; Klein CJ; Naddaf E; Staff NP; Liewluck T; Hammack JE; Sandroni P; Finnes H; Mauermann ML
JAMA Neurol; 2017 Oct; 74(10):1216-1222. PubMed ID: 28873125
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-Induced Eruptive Keratoacanthomas and Lichen Planus in a Lung Cancer Patient.
Tembunde Y; Dika MN
Cureus; 2023 Aug; 15(8):e43402. PubMed ID: 37706118
[TBL] [Abstract][Full Text] [Related]
12. Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment.
Star P; Jackett LA; Cheung K; Wilmott JS; Ho G; Smith A; Long GV; Scolyer RA; Martin LK
Dermatol Ther; 2022 Jun; 35(6):e15472. PubMed ID: 35347815
[TBL] [Abstract][Full Text] [Related]
13. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous resolution of eruptive papules following ablative laser resurfacing-Case report and review of laser-associated eruptive keratoacanthomas.
Nanda R; Cohen JL
J Cosmet Dermatol; 2024 Jun; 23(6):1936-1939. PubMed ID: 38572518
[TBL] [Abstract][Full Text] [Related]
15. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
[TBL] [Abstract][Full Text] [Related]
17. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
[TBL] [Abstract][Full Text] [Related]
18. Generalized eruptive keratoacanthomas of Grzybowski.
Anzalone CL; Cohen PR
Int J Dermatol; 2014 Feb; 53(2):131-6. PubMed ID: 24321108
[TBL] [Abstract][Full Text] [Related]
19. [Sorafenib-induced multiple eruptive keratoacanthomas].
Jantzem H; Dupre-Goetghebeur D; Spindler P; Merrer J
Ann Dermatol Venereol; 2009 Dec; 136(12):894-7. PubMed ID: 20004316
[TBL] [Abstract][Full Text] [Related]
20. PD1 inhibitor induced inverse lichenoid eruption: a case series.
Sethi M; Garg V; Lee JB; Yang S
Dermatol Online J; 2020 Dec; 26(12):. PubMed ID: 33423421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
